SCREEN Yourself for Cancer
SCREEN Yourself for Cancer (Self-Collection Research Examining Engagement and Navigation)
This randomized controlled trial will evaluate whether evidence-based self-sampling tools improve the cancer screening process among underscreened patients. Participants who are eligible but out-of-date for colorectal cancer screening, cervical cancer screening, or both will be randomized to either usual practice or an intervention that includes mailed self-sampling tools for the appropriate cancer screening test. Primary outcomes include screening initiation (within 12 months of enrollment) and screening completion (within 18 months of enrollment), for each cancer type. Secondary outcomes include repeat screening adherence and receipt of diagnostic resolution following abnormal screening results.
Przegląd badań
Status
Status
Warunki
Warunki
Interwencja / Leczenie
Interwencja / Leczenie
Szczegółowy opis
In the US, tens of thousands of people die from screen-preventable cancers each year. Failures occur across the entire cancer screening process, from screening initiation, to screening completion (i.e., receipt of a normal screening result or diagnostic resolution after an abnormal result), to repeat screening. Providing patients with self-sampling tools can improve these outcomes. These self-sampling tools (fecal immunochemical test [FIT] for colorectal cancer [CRC] screening and self-collected human papillomavirus [HPV] test for cervical cancer screening) enable patients to collect a sample at home and send it to a lab for testing. These tests are highly accurate and acceptable but not well-integrated into clinical care. Further, their impacts on screening completion and repeat screening are not well-studied. The proposed study is a rigorous, two-arm, parallel-groups randomized controlled trial to assess screening initiation, screening completion, and repeat screening among patients who are eligible but out-of-date with screening for CRC and/or cervical cancer. The study team will generate a census of patients in our healthcare system who meet study inclusion criteria and undertake stratified random selection to select patients for inclusion in the study. Patients will be randomized (1:1) to study arm: Usual practice arm, in which patients receive a letter informing them that they are out-of-date with cancer screening and encouraging them to make an appointment to get screened, and Self-sampling arm, in which patients receive self-sampling tool(s) and are encouraged to use it for cancer screening. As appropriate, patients will receive screening reminders, diagnostic resolution follow-up procedures, and 1-year repeat FIT for CRC screening. The study team will collect data from electronic health records and surveys. The study Aims are as follows:
Aim 1: Investigate between-arms differences in screening initiation. Aim 2: Examine between-arms differences in downstream screening outcomes. Aim 3: Identify mediators and moderators that impact the cancer screening process.
The recruitment goal for this study is 852 patients, including 542 who are eligible but out-of-date for CRC screening; 110 who are eligible but out-of-date for cervical cancer screening; and 200 who are eligible but out-of-date for both screenings. This sample will support rigorous, well-powered analyses of our Aims and hypotheses, using bivariate and multivariable analyses (including mediation and moderation analysis). This study will demonstrate the impact of self-sampling tools for the entire cancer screening process, which has significant implications for clinical care, public health, and behavioral research. The findings from the proposed study will support our long-term goal of identifying strategies to increase participation in the cancer screening process and to reduce screen-preventable cancer mortality in the US.
Typ studiów
Typ studiów
Zapisy (Szacowany)
Zapisy
Faza
Faza
- Nie dotyczy
Kontakty i lokalizacje
Kontakt w sprawie studiów
Kontakt w sprawie studiów
- Nazwa: Leonard A. Kishel, MA
- Numer telefonu: 321657 717-531-0003
- E-mail: lkishel@pennstatehealth.psu.edu
Kopia zapasowa kontaktu do badania
- Nazwa: Jennifer L. Moss, PhD
- Numer telefonu: 323429 717-531-0003
- E-mail: jmoss1@pennstatehealth.psu.edu
Lokalizacje studiów
-
-
Pennsylvania
-
Hershey, Pennsylvania, Stany Zjednoczone, 17033
- Pennsylvania State University College of Medicine
-
Kontakt:
- Leonard A Kishel, MA
- Numer telefonu: 321657 7175310003
- E-mail: lkishel@pennstatehealth.psu.edu
-
Kontakt:
- Jennifer L Moss, PhD
- Numer telefonu: 323429 7175310003
- E-mail: jmoss1@pennstatehealth.psu.edu
-
-
Kryteria uczestnictwa
Kryteria kwalifikacji
Kryteria kwalifikacji
Wiek uprawniający do nauki
Akceptuje zdrowych ochotników
Płeć kwalifikująca się do nauki
Opis
Inclusion Criteria:
- active patient at Penn State Health Department of Family and Community Medicine
- patients eligible but out-of-date for routine colorectal cancer screening and/or routine cervical cancer screening
- able to read and write in English, Spanish, or Nepali
Exclusion Criteria:
- patients ineligible for routine colorectal and/or cervical cancer screening
- patients up-to-date on routine colorectal and/or cervical cancer screening (as applicable)
- not able to read and write in English, Spanish, or Nepali
Plan studiów
Jak projektuje się badanie?
Szczegóły projektu
- Główny cel: Ekranizacja
- Przydział: Randomizowane
- Model interwencyjny: Przydział równoległy
- Maskowanie: Podwójnie
Liczba ramion
Broń i interwencje
Grupa uczestników / ArmGrupa uczestników / Arm |
Interwencja / LeczenieInterwencja / Leczenie |
|---|---|
|
Aktywny komparator: Usual Practice
Participants will receive standard health system outreach (i.e., mailed reminders) encouraging completion of recommended colorectal and/or cervical cancer screening through routine clinical care pathways. |
Routine mailed reminders and health system communication encouraging completion of guideline-recommended cancer screening. |
|
Eksperymentalny: Self-sampling arm
Participants will receive a package containing self-sampling tool(s) for colorectal and/or cervical cancer screening, encouraging them to complete screening with the self-sampling tool. |
Education materials, instructions, and support documents accompanying mailed self-sampling kits. |
Co mierzy badanie?
Podstawowe miary wyniku
Podstawowe miary wyniku
Miara wyniku |
Opis środka |
Ramy czasowe |
|---|---|---|
|
Colorectal cancer screening initiation
Ramy czasowe: 12 months after baseline
|
The percentage of patients in each study arm who initiate colorectal cancer screening between baseline and 12-months follow-up, according to electronic health record data. |
12 months after baseline
|
|
Cervical cancer screening initiation
Ramy czasowe: 12 months after baseline
|
The percentage of patients in each study arm who initiate cervical cancer screening between baseline and 12-months follow-up, according to electronic health record data. |
12 months after baseline
|
|
Colorectal cancer screening completion
Ramy czasowe: 18 months after baseline
|
The percentage of patients in each study arm who complete colorectal cancer screening (i.e., receipt of a normal screening result or diagnostic resolution after an abnormal result) between baseline and 18-months follow-up, according to electronic health record data. |
18 months after baseline
|
|
Cervical cancer screening completion
Ramy czasowe: 18 months after baseline
|
The percentage of patients in each study arm who complete cervical cancer screening (i.e., the receipt of a normal screening result or diagnostic resolution after an abnormal result) between baseline and 18-months follow-up, according to electronic health record data. |
18 months after baseline
|
Miary wyników drugorzędnych
Miary wyników drugorzędnych
Miara wyniku |
Opis środka |
Ramy czasowe |
|---|---|---|
|
Repeat colorectal cancer screening
Ramy czasowe: 24 months after baseline
|
Among patients who undergo colorectal cancer screening with FIT and receive normal test results, the percentage of patients who repeat colorectal cancer screening with FIT one year later, within 24 months of baseline, according to electronic health record data. |
24 months after baseline
|
|
Receipt of diagnostic resolution after abnormal cancer screening results
Ramy czasowe: 6 months after initiating cancer screening
|
Among patients who undertake cancer screening and receive abnormal test results, the percentage of patients who receive diagnostic resolution procedures within 6 months of the test results, according to electronic health record data. |
6 months after initiating cancer screening
|
Współpracownicy i badacze
Sponsor
Sponsor
Współpracownicy
Współpracownicy
Śledczy
Śledczy
- Główny śledczy: Jennifer L. Moss, PhD, Pennsylvania State University College of Medicine
Daty zapisu na studia
Główne daty studiów
Rozpoczęcie studiów (Szacowany)
Rozpoczęcie studiów
Zakończenie podstawowe (Szacowany)
Zakończenie podstawowe
Ukończenie studiów (Szacowany)
Ukończenie studiów
Daty rejestracji na studia
Pierwszy przesłany
Pierwszy przesłany
Pierwszy przesłany, który spełnia kryteria kontroli jakości
Pierwszy przesłany, który spełnia kryteria kontroli jakości
Pierwszy wysłany (Rzeczywisty)
Pierwszy wysłany
Aktualizacje rekordów badań
Ostatnia wysłana aktualizacja (Rzeczywisty)
Ostatnia wysłana aktualizacja
Ostatnia przesłana aktualizacja, która spełniała kryteria kontroli jakości
Ostatnia przesłana aktualizacja, która spełniała kryteria kontroli jakości
Ostatnia weryfikacja
Ostatnia weryfikacja
Więcej informacji
Terminy związane z tym badaniem
Słowa kluczowe
Inne numery identyfikacyjne badania
Inne numery identyfikacyjne badania
- STUDY00029563
- 1R37CA309199-01A1 (Grant/umowa NIH USA)
Plan dla danych uczestnika indywidualnego (IPD)
Planujesz udostępniać dane poszczególnych uczestników (IPD)?
Opis planu IPD
The study team will make scientific data and associated documentation publicly available through an institutional repository upon study completion. Deidentified participant-level data supporting published findings may be shared upon reasonable request, subject to institutional approvals and applicable data use agreements.
Ramy czasowe udostępniania IPD
Beginning six months after final data collection, with no end date.
Kryteria dostępu do udostępniania IPD
Deidentified data and supporting information will be available to anyone through a publicly accessible, online data repository.
Typ informacji pomocniczych dotyczących udostępniania IPD
- PROTOKÓŁ BADANIA
- SOK ROŚLINNY
- ICF
- ANALITYCZNY_KOD
- CSR
Informacje o lekach i urządzeniach, dokumenty badawcze
Bada produkt leczniczy regulowany przez amerykańską FDA
Bada produkt urządzenia regulowany przez amerykańską FDA
Te informacje zostały pobrane bezpośrednio ze strony internetowej clinicaltrials.gov bez żadnych zmian. Jeśli chcesz zmienić, usunąć lub zaktualizować dane swojego badania, skontaktuj się z register@clinicaltrials.gov. Gdy tylko zmiana zostanie wprowadzona na stronie clinicaltrials.gov, zostanie ona automatycznie zaktualizowana również na naszej stronie internetowej .